Table 1.
Comparative activity of imatinib, sunitinib, regorafenib and imatinib rechallenge in patients with advanced or metastatic gastrointestinal stromal tumor.
| Imatinib (n = 147) [Blanke et al. 2008a] |
Sunitinib (n = 207) [Demetri et al. 2012] |
Regorafenib (n = 133) [Demetri et al. 2013] |
Imatinib rechallenge (n = 41) [Kang et al. 2013] |
|
|---|---|---|---|---|
| ORR (%) | 68.1 | 7 | 4.5 | 0 |
| SD12 weeks (%) | 15.6 | 53 | 48.1 | 32 |
| TTP/PFS (months) | 24 | 6.1 | 4.8 | 1.8 |
ORR includes complete response and partial response.
ORR, overall response rate; PFS, progression-free survival; SD, stable disease; TTP, time to treatment progression.